BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tilatamig samrotecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tilatamig samrotecan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04541108-7689@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Tilatamig samrotecan: Phase 1 readout est. (NCT04541108)
DESCRIPTION:Tilatamig samrotecan\, phase 1.\nStudy: Phase 0 Master Protocol
  for CIVO Intratumoral Microdosing of Anti-Cancer Therapies\nEstimated pri
 mary completion: December 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tilatamig-samrotecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04541108
URL:https://assetmemo.bio/drug/tilatamig-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
